Related Experiment Video
Updated: Jul 24, 2025

Identification of Rare Bacterial Pathogens by 16S rRNA Gene Sequencing and MALDI-TOF MS
Published on: July 11, 2016
Necrotizing Pancreatitis Infected with Stenotrophomonas maltophilia: An Emerging Rare Multidrug-Resistant Organism
Sophia Dar1, Nooraldin Merza2, Maryam Haider3
1Department of Internal Medicine, Hackensack University Medical Center, Hackensack, NJ, USA.
Abstract:
Stenotrophomonas maltophilia (SM) is a multidrug-resistant, Gram-negative (GN) bacillus that is an increasingly recognized nosocomial and environment pathogen. It is intrinsically resistant to carbapenems, a drug commonly utilized in the management of necrotizing pancreatitis (NP). We report a 21-year-old immunocompetent female with NP complicated by pancreatic fluid collection (PFC) infected with SM. One-third of patients with NP will develop infections by GN bacteria, while broad-spectrum antibiotics, including carbapenems, cover most infections, trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line treatment antibiotic for SM. This case is critical because it highlights a rare pathogen that should be considered a causal pathogen in patients who do not respond to their care plan.
Insights
Stenotrophomonas maltophilia, a multidrug-resistant pathogen, can complicate necrotizing pancreatitis. Trimethoprim-sulfamethoxazole is the recommended treatment for this rare but critical infection.
Area of Science:
- Infectious Diseases
- Microbiology
- Critical Care Medicine
Background:
- Stenotrophomonas maltophilia (SM) is a multidrug-resistant Gram-negative bacillus.
- SM is an emerging nosocomial and environmental pathogen.
- It exhibits intrinsic resistance to carbapenems, a common treatment for necrotizing pancreatitis (NP).
More Related Videos
11:35Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
Published on: May 4, 2018
04:01Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis
Published on: September 8, 2022
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pyelonephritis II: Diagnostic Studies and Management